[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Utah\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":596},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,142,0,25,[9,42,65,89,113,131,152,181,213,246,266,296,314,340,358,375,393,412,429,450,480,504,524,547,573],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100533531","phase-1-pilot-study-of-anti-cd19-chimeric-antigen-receptor-t-cells-car-t-cells-for-the-treatment-of-relapsedrefractory-cd19-malignancies-100533531",false,"NCT06227026","Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed\u002FRefractory CD19+ Malignancies","PRODIGY","Inclusion Criteria:\n\n* Subjects aged ≥ 18 years.\n* Histologically confirmed relapsed or refractory CD-19+ malignancy, including: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), Chronic Lymphocytic Leukemia (CLL)\u002FRichter's syndrome. CD-19+ must be confirmed by immunohistochemistry or flow cytometry analysis.\n* Subjects who have relapsed or refractory disease after failing at least 2 or more prior lines of therapy.\n* ECOG Performance Status ≤ 2.\n* Life expectancy \\> 12 weeks.\n* Willing to consent to 15 years of follow-up as part of IRB 110692: Long-Term Evaluation of the Biology and Outcomes of Hematopoietic Stem Cell Transplantation\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Absolute neutrophil count (ANC) ≥ 500\u002Fmm3\n    * Platelet count ≥ 10,000\u002Fmm3\n    * Hemoglobin ≥ 8 g\u002FdL\n  * Hepatic:\n\n    * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN).\n    * AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN\n  * Renal:\n\n    * Serum Creatinine ≤ 2 x institutional upper limit of normal (ULN) or eGFR \\>30 ml\u002Fmin\u002F1.73m2\n* For subjects of childbearing potential: Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Subjects \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * Subjects ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago\n* Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.\n* Recovery to baseline or ≤ Grade 2 CTCAE v5.0 from toxicities related to any prior cancer therapy, unless considered stable by the treating investigator.\n* Adequate venous access.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Step 2 Eligibility Confirmation\n\n  * The following criteria must be confirmed within 7 days prior to lymphodepletion. If all criteria are not met, lymphodepletion should be delayed.\n\n    * Confirmation of successful CAR-T manufacturing.\n    * No evidence or suspicion of an infection.\n    * Serum Creatinine ≤ 2 x institutional upper limit of normal (ULN) or eGFR \\>30 ml\u002Fmin\u002F1.73m2\n    * No worsening of clinical status compared to either the initial eligibility criteria that would, in the opinion of the treating physician, significantly increase the risk from lymphodepleting chemotherapy or exclude them from treatment with study CAR-T therapy.\n* Step 3 Eligibility Confirmation\n\n  * The following criteria must be confirmed prior to CAR-T therapy. If all criteria are not met, CAR-T therapy should be delayed.\n\n    * No worsening of clinical status compared to either the initial eligibility criteria that would, in the opinion of the treating physician, significantly increase the risks from treatment with CAR-T therapy.\n    * Confirmation that washout periods outlined in section 6.6 and Appendix 10 have been followed.\n\nExclusion Criteria:\n\n* Autologous or allogeneic stem cell transplant or CAR-T therapy within 6 weeks of planned CAR-T cell infusion.\n* Subjects with active infection that requires systemic treatment\n* History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.\n* Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of child bearing potential must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.\n* Receiving other investigational agents.\n* Confirmation that washout periods listed in Appendix 10 have been followed.\n* Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.\n* The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and\u002For will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6). Patients with transformed disease are allowed.\n* Known brain metastases or cranial epidural disease. Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the first dose of study treatment.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n    * QTc prolongation defined as a QTcF \\> 500 ms.\n    * Known congenital long QT.\n    * Left ventricular ejection fraction \\\u003C 55%.\n    * Uncontrolled hypertension defined as ≥ 140\u002F90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the drug through a feeding tube\\], social\u002F psychological issues, etc.)\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or seropositive HIV. Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).\n* Subjects taking prohibited medications as described in Section 6.6 and Appendix 10. Unless otherwise stated, a washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.\n* Subjects with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells.\n\nThis study will utilize a staggered enrollment design with a safety observation period.",[27,28],"Acute Lymphoblastic Leukemia","Diffuse Large B Cell Lymphoma","RECRUITING","2026-08-19",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":33},"2024-02-20",{"date":37,"type":21},"2028-05",{"name":39,"class":40},"University of Utah","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100608578","phase-2-nurturing-exercise-routine-for-greater-improvement-in-zest-and-energy-on-enhertu-100608578","NCT07203378","Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu","ENERGIZE: Engagement With a Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu: A Single-Center Pilot Study","ENERGIZE","Inclusion Criteria:\n\n* Subject aged ≥ 18 years\n* Diagnosis of locally advanced\u002Funresectable or metastatic breast cancer. Note: Patients with High-Risk HER-2 + breast cancer after completion of neoadjuvant chemotherapy requiring adjuvant Enhertu are allowed at the discretion of the treating physician.\n* Has received 3 or 4 cycles of Enhertu and is expected to continue treatment for at least 12 weeks. Note: HER-2 targeted systemic therapy (e.g. Trastuzumab and\u002For Pertuzumab) in conjunction with Enhertu is allowed.\n* Able and willing to participate in the interventional aerobic exercise and resistance exercises.\n* Currently following standard of care contraception requirements and willing to continue following these requirements for the duration of therapy.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Experiencing clinical fatigue symptoms in the opinion of the investigator.\n* Subject has completed the ACSM exercise preparticipation health screening and is, in the opinion of the investigator, fit to participate in this study.\n\nExclusion Criteria:\n\n-Currently adhering to national physical activity guidelines for resistance training, as defined as participating in structured resistance training ≥ two days per week.\n\n* Structured is defined as time set aside in the subject's day to workout.\n* Resistance training is defined as exercises which use weights, bands, or body weight (e.g., squats or push-ups).\n\nAND Currently participating in structured moderate-intensity aerobic exercise for ≥ 150 minutes per week.\n\n* Moderate-intensity exercise is defined as activities where the subject can talk but not sing.\n* Aerobic exercise includes, but is not limited to, walking, swimming, cycling, running, rowing, hiking, and elliptical.\n\n  * Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n  * Participants taking prohibited medications as described in Section 7.4.1.",{"count":51,"type":21},80,[53],"PHASE2","The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are receiving Enhertu.",[56],"Metastatic Breast Cancer","2026-08-18",{"date":59,"type":33},"2026-08-20",{"date":61,"type":33},"2025-11-04",{"date":63,"type":21},"2028-11",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":41},"100630314","early-phase-1-motorized-prostheses-for-lower-limb-amputees-100630314","NCT07486063","Motorized Prostheses for Lower-limb Amputees","Lightweight Motorized Prostheses for Lower-limb Amputees","Our inclusion criteria will be\n\n* Above-knee amputation\n* K2\u002FK3\u002FK4 ambulators\n* At least 18 years old\n* At least one year since amputation\n* At least six months since the definitive prosthesis fitting\n* Currently prescribed and using a mechanically passive or microprocessor-controlled prosthesis\n\nOur exclusion criteria will be\n\n* Over 350 lbs. body weight, the weight limit for our safety suspension systems\n* Cognitive deficits or visual impairment that could impair their ability to give informed consent or to follow simple instructions during the experiments\n* Pregnant women due to elevated safety concerns for this population\n* Co-morbidity that limits their ability to participate in the study protocol (e.g., stroke, pacemaker placement that would interfere with the powered prosthesis, severe ischemia, cardiac disease, etc.)\n* Adults who are unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Individuals who use a wheelchair for mobility both outdoors and indoors because they may not be able to perform the necessary activities with their passive prosthesis or the powered prosthesis\n* Prisoners, due to concerns with informed consent",true,"80 Years",{"count":75,"type":21},40,[77],"EARLY_PHASE1","The investigators will assess biomechanical and functional mobility outcomes in individuals with unilateral, above-knee amputations using different knee\u002Fankle configurations of a lightweight powered prosthesis and different volitional controllers in individuals with unilateral, above-knee amputations.",[80],"Lower-Limb Amputation","2026-08-12",{"date":83,"type":33},"2026-08-14",{"date":85,"type":33},"2025-07-01",{"date":87,"type":21},"2032-06",{"name":39,"class":40},{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":41},"100630665","at-home-paracentesis-for-women-with-cancer-related-malignant-ascites-paracentesis-100630665","NCT07490626","At-Home Paracentesis for Cancer-Related Malignant Ascites (Paracentesis)","A Pilot Study of At-Home Paracentesis for Cancer-Related Malignant Ascites: A Decentralized Interventional Treatment Trial (Paracentesis)","Paracentesis","Inclusion Criteria:\n\n* Participants aged ≥ 18 years\n* Able to speak and understand English.\n* Has completed an initial clinic-based paracentesis procedure.\n* Confirmed diagnosis of cancer.\n* Symptoms related to ascites requiring procedure in the opinion of the investigator.\n* Eligible to receive an ultrasound-guided paracentesis procedure at home in the opinion of the investigator.\n* If applicable, participant is able to safely hold anticoagulant therapy per institutional standards prior to the procedure in the opinion of the investigator.\n* For participants of child-bearing potential, participant is following standard of care guidelines for contraception.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Rapidly deteriorating condition or suspected bowel obstruction.\n* Large ventral hernias or prior complications from paracentesis.\n* Need for concurrent procedures requiring hospital resources.\n* Known lack of safe environment or inability to obtain sterile conditions at home.\n* Any condition that would, in the Investigator's judgment, contraindicate the participant's participation in the procedure or clinical study due to safety concerns or compliance with clinical study procedures. For example,\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.",{"count":98,"type":21},20,[100],"NA","The goal of this study is to evaluate the change in symptoms for cancer-related malignant ascites who complete an at-home paracentesis procedure.",[103],"Malignant Ascites","NOT_YET_RECRUITING","2026-08-11",{"date":107,"type":33},"2026-08-13",{"date":109,"type":21},"2026-08",{"date":111,"type":21},"2028-10",{"name":39,"class":40},{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":130,"locationsCount":41},"100608493","simulation-free-single-fraction-palliative-radiation-therapy-for-treatment-of-bone-metastases-100608493","NCT07202273","Simulation-Free, Single-Fraction Palliative Radiation Therapy for Treatment of Bone Metastases","A Feasibility Study of Simulation-Free, Single-Fraction Palliative Radiation Therapy for Treatment of Bone Metastases (SIM-FREE RT)","SIM-FREE RT","Inclusion Criteria:\n\n* Participant aged ≥ 18 years.\n* Diagnosis of any cancer with one to two sites of painful and treatable metastatic bone lesions.\n* Bone metastases are causing pain or instability in the opinion of the treating investigator.\n* Amenable to single fraction radiation therapy per the discretion of the treating physician.\n* CT collected within 60 days of registration with adequate visualization of target site as determined by the treating investigator.\n* ECOG Performance Status ≤ 2.\n* Participants must adhere to the following sex and contraceptive\u002Fbarrier requirements:\n\n  * If participant is of childbearing potential, they must have a negative pregnancy test ≤ 14 days before the planned date of radiation therapy. This may be completed on the day of radiation if results from the pregnancy test are available for review before treatment.\n  * For participants of non-child bearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:\n\n    * \\\u003C 50 years of age:\n\n      * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n      * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n\n        ---≥ 50 years of age:\n      * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n      * Had radiation-induced menopause with last menses \\>1 year ago; or\n      * Had chemotherapy-induced menopause with last menses \\>1 year ago\n    * Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Evidence of spinal cord compression caused by the bone metastases to be treated.\n* Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n* Participants taking prohibited medications as described in Section 6.7.1.",{"count":75,"type":21},[100],"The goal of this study is to provide proof that patients can be treated with simulation-free, single-fraction palliative radiation therapy with a single in-person visit.",[125],"Bone Metastases",{"date":107,"type":33},{"date":128,"type":33},"2025-11-03",{"date":111,"type":21},{"name":39,"class":40},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":139,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":41},"100486424","phase-1-dose-escalation-study-of-cabozantinib-in-combination-with-lutetium-177-177lu-psma-617-in-patients-with-metastatic-castration-resistant-prostate-cancer-100486424","NCT05613894","Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer","A Phase Ib Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","CaboLu","Inclusion Criteria:\n\n* Male subject aged ≥ 18 years.\n* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology.\n* Prior orchiectomy and\u002For ongoing androgen-deprivation therapy and a castrate level of serum testosterone (\\\u003C50 ng\u002FdL or \\\u003C1.7 nmol\u002FL).\n* Prior treatment with at least one prior Novel Hormone Therapy (NHT), defined as second-generation anti-androgen therapies that include, but are not limited to, abiraterone acetate, enzalutamide, apalutamide, and darolutamide.\n* Must be eligible for therapy with 177Lu-PSMA-617 and have ≥ 1 PSMA-positive lesion per treating investigator.\n* Must have progressive mCRPC per the treating investigator.\n* ECOG Performance Status ≤ 1.\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Absolute neutrophil count (ANC) ≥ 1500\u002FµL without granulocyte colony-stimulating factor support\n    * White blood cell count ≥ 3000\u002FµL.\n    * Platelet count ≥ 100,000\u002FµL\n    * Hemoglobin ≥ 9g\u002FdL\n    * Serum albumin ≥ 2.5 g\u002Fdl\n    * PT\u002FINR or partial thromboplastin time (PTT) test \\\u003C 1.3x the laboratory ULN\n  * Hepatic:\n\n    * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)\n    * For subjects with Gilbert's disease: ≤ 3x ULN\n    * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit of normal (ULN).\n  * Renal:\n\n    * Urine protein\u002Fcreatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol), or 24-h urine protein ≤ 1 g\n    * Estimated creatinine clearance ≥ 50 mL\u002Fmin by Cockcroft-Gault formula Males: ((140-age)×weight\\[kg\\])\u002F(serum creatinine \\[mg\u002FdL\\]×72)\n* Sexually active fertile patients and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 6 months after the last dose of study treatment in accordance with section 5.4.2.\n* Recovery to baseline or ≤ Grade 1 CTCAE v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Patients must have a life expectancy \\>3 months.\n\nExclusion Criteria:\n\n* Receiving other investigational anti-cancer agents.\n* Prior treatment with cabozantinib\n* Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation within 6 months prior to randomization.\n* Previous PSMA-targeted radioligand therapy\n* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.\n* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n* Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment.\n* Systemic treatment with radionuclides within 6 weeks before first dose of study treatment.\n* Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n* Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis).\n* Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment.\n* Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n* Major surgery within 4 weeks prior to starting study drug, minor surgery within 10 days, or subjects who have not fully recovered from major surgery.\n* Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%), such as locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast.\n* Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n  * Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH)\n  * Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before the first dose of study treatment.\n    * Subjects with a diagnosis of incidental, subsegmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation (see exclusion criterion 14) for at least 1 week before first dose of study treatment.\n    * Uncontrolled hypertension defined as sustained blood pressure (BP) ≥ 150 mm Hg systolic or \\>90 mmHg diastolic despite optimal antihypertensive treatment.\n  * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n    * The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n    * Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.\n    * Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, social\u002F psychological issues, etc.)\n* Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n* Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n* Lesions invading or encasing any major blood vessels\n* Other clinically significant disorders that would preclude safe study participation.\n\n  * Serious non-healing wound\u002Fulcer\u002Fbone fracture.\n  * Uncompensated\u002Fsymptomatic hypothyroidism.\n  * Moderate to severe hepatic impairment (Child-Pugh B or C).\n  * Known history of COVID-19 unless the subject has clinically recovered from the disease at least 30 days prior to first dose of study treatment.\n* Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment or minor surgeries within 10 days before first dose of study treatment.\n* Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment.\n\n  --Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment.\n\n  --Note: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n* Inability to swallow tablets\n* Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.\n\n  --Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.\n* Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Subjects taking prohibited medications as described in Section 6.8.2. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.","MALE",{"count":141,"type":21},33,[24],"This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC. The primary hypothesis is that cabozantinib with 177Lu-PSMA will be safe and have efficacy in patients with mCRPC. The dose-escalation phase (Part 1) will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the MTD and\u002For recommended dose and schedule for the subsequent expansion phase (Part 2).",[145],"Metastatic Castration-resistant Prostate Cancer",{"date":81,"type":33},{"date":148,"type":33},"2023-07-14",{"date":150,"type":21},"2028-12",{"name":39,"class":40},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":162,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},"100140521","assessing-changes-in-myocardial-tissue-and-blood-in-patients-with-advanced-heart-disease-100140521","NCT01099982","Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease","Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease, Effects of Mechanical Unloading on Myocardial Function and Structure in Humans","Inclusion Criteria:\n\n* \\>18 years of age diagnosed with heart failure undergoing either LVAD implantation or heart transplantation\n* 13 to 18 years of age, specifically, older children with heart failure whose body mass index is large enough to accommodate and LVAD\n\nExclusion Criteria:\n\n* Neither patient nor patient representative understands spoken English\n* Neither patient nor patient's personal representative is willing to give written consent for participation.","13 Years",{"count":161,"type":21},300,"OBSERVATIONAL","Hypothesis:\n\nTissue and serum samples collected from end-stage heart failure patients receiving left ventricular assist device implantation (LVAD) or heart transplantation will provide information regarding the basic science of heart disease. Tissue and serum samples collected from a limited numbers of \"healthy controls\" (donor grafts that were not utilized for heart transplantation) will serve as a comparator in research database projects.\n\nDesign:\n\nThis is a registry project; there are no investigational treatments, drug or procedures associated with participation in registry activities. This project is an organized functional data and tissue data gathering and storing (database) endeavor with specific focus on the functional, structural, and molecular aspects of heart failure. Data collection will not immediately influence the course of treatment for any patient.",[165],"Congestive Heart Failure",[165,167,168,169,170,171,172,173],"Left Ventricular Assist Device","LVAD","Myocardium","Remodeling","Microvasculature","Fibrosis","Cardiac Transplant",{"date":107,"type":33},{"date":176,"type":33},"2008-09",{"date":178,"type":21},"2030-01",{"name":39,"class":40},3,{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":72,"sex":189,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":41},"100651842","transforming-maternal-mental-health-care-100651842","NCT07766174","Transforming Maternal Mental Health Care","Transforming Maternal Mental Health Care Using Innovative Digital Solutions for the Intermountain West","IUFU","Inclusion Criteria:\n\n* Pregnant people receiving care at University of Utah Clinics\n* Less than 14 weeks gestation at enrollment\n\nExclusion Criteria:\n\n* Patients enrolled in other studies utilizing remote monitoring","FEMALE","45 Years",{"count":192,"type":21},50,[100],"The overall objective of this pilot study is to assess the feasibility of a RCT comparing Lōvu-augmented with usual prenatal care at UU. This would be a critical next step toward our long-term goal to identify technology-based interventions to improve maternal mental health in the Intermountain West. Our central hypothesis is that Lōvu will be both feasible and have high patient and clinician satisfaction, and that Lōvu-generated data will be a promising substrate for AI-based mental health risk stratification.",[196],"Perinatal Mental Health",[198,199,200,201,202,203,204,205],"Pregnant","Mental Health Check-Ins and Support","App","Care Navigator","Real-Time Vital Signs Data","Nutrition and Wellness Guidance","Education and Birthing Support","Exercise and Pelvic Floor Rehab","2026-08-10",{"date":83,"type":33},{"date":209,"type":21},"2026-09-01",{"date":211,"type":21},"2032-04-30",{"name":39,"class":40},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":220,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":232,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},"100605853","developing-an-innovative-decision-support-tool-for-pediatric-neuromuscular-scoliosis-100605853","NCT07167927","Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis","Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis - Aims 2 and 3","Inclusion criteria:\n\n* Parent-child dyads of children with neuromuscular scoliosis who speak English and Spanish.\n* Child is between ages 8-21 years of age and they are coming into the pediatric orthopaedic surgery clinic for consultation about potential surgery for NMS.\n* NMS is defined as having neurologic impairment (NI) and scoliosis using relevant ICD-9 or ICD-10 codes from Feudtner, et al. 2014 or Berry, et al. 2012. or a qualifying diagnosis per the Pediatric Spine Study Group definition of NMS.\n* All pediatric orthopaedic surgeons and neurosurgeons who treat neuromuscular scoliosis at our study sites will be eligible participants.\n\nExclusion criteria:\n\n* Families whose child with NMS is less than 8 years of age at time of orthopaedic consultation because surgery at a younger age usually indicates an atypical case.\n* Children with the diagnosis of Becker's muscular dystrophy due to potential disease modifying therapies that may alter curve progression.","8 Years",{"count":222,"type":21},110,[100],"The goal of this pilot hybrid type I efficacy\u002Fimplementation trial is to assess a newly developed decision support tool patients, parents, and providers to use during surgical treatment decision making for neuromuscular scoliosis (NMS). Results from this pilot will inform the design of a future larger effectiveness trial of the decision support tool.\n\nParticipants will either receive usual care or receive the decision support tool. Researchers will assess the decision made, decision quality, individual affective, cognitive, and behavioral effects, and feasibility and acceptability of tool use. They will also collect potential barriers and facilitators to implementation and feedback about the tool and study design to maximize likelihood of successful deployment of the tool into clinical practice and inform the design of a future trial. The outcomes measures will be used to inform potential effect size estimates to inform a future trial.",[226,227,228,229,230,231],"Children With Medical Complexity (CMC)","Multiple Chronic Conditions","Neuromuscular Scoliosis","Shared Decision Making","Decision Support Systems, Clinical","Decision Aids",[233,234,235,236,237],"children with medical complexity","shared decision making","values clarification","uncertainty communication","decision support tool","2026-08-06",{"date":206,"type":33},{"date":241,"type":33},"2025-10-21",{"date":243,"type":21},"2027-03-31",{"name":39,"class":40},2,{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":180},"100562775","loncastuximab-tesirine-and-rituximab-following-stereotactic-radiosurgery-in-patients-with-central-nervous-system-lymphomas-solar-100562775","NCT06607549","Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)","A Phase 1 Study of Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas","SOLAR","Inclusion Criteria:\n\n* Participant aged ≥ 18 years\n* ECOG Performance Status ≤ 3\n* Histologically confirmed primary CNS lymphoma or secondary diffuse large B-cell lymphoma (DLBCL) with CNS involvement with either:\n\n  * Relapsed or refractory disease with at least 1 prior therapy OR\n  * Ineligible for high-dose methotrexate-based therapy as determined by the treating physician, including previously untreated patients. Examples of medical conditions for which a patient could be considered ineligible for high-dose methotrexate include but not limited to renal impairment, liver disease, heart failure.\n\n    * Note: For patients with a history of histologically documented systemic DLBCL with CNS relapse, a biopsy of the CNS lesion is recommended but not required.\n* Must be a candidate for SRS. Lesion size must be \\\u003C 6 cm and the number of lesions must be \\\u003C 10.\n* Must have evaluable disease. This includes radiographic evidence of parenchymal disease or parenchymal disease and disease detected in the CSF.\n\n  * Patients with vitreous or retinal involvement alone are not eligible.\n  * Patients with leptomeningeal disease or spinal cord disease are not eligible.\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Absolute neutrophil count ≥ 1000 cells\u002Fmm3 (1.00 x 109\u002FL) independent of G-CSF support (i.e. no G-CSF within the past 3 days) unless there is documented bone marrow involvement.\n    * Platelet count ≥ 75,000 cells\u002Fmm3 (75 x 109\u002FL) independent of transfusion support (i.e. no transfusion within the past 3 days) unless there is documented bone marrow involvement.\n    * Hemoglobin ≥ 8 g\u002FdL (≥ 80 g\u002FL) independent of transfusion support (i.e. no transfusion within the past 3 days) unless there is documented bone marrow involvement.\n  * Hepatic:\n\n    ---Total bilirubin ≤ 2.0 mg\u002FdL (unless bilirubin rise is due to Gilbert's syndrome), if total bilirubin is \\> 2.0 mg\u002FdL, the subject is eligible for the study if the direct bilirubin is normal; transaminases (AST\u002FALT) ≤2.5 x upper limit of normal (ULN)\n  * Renal:\n\n    * Estimated creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft-Gault formula:\n\n      * Males: ((140-age)×weight\\[kg\\])\u002F(serum creatinine \\[mg\u002FdL\\]×72)\n      * Females: (((140-age)×weight\\[kg\\])\u002F(serum creatinine \\[mg\u002FdL\\]×72))×0.85\n* For subjects of childbearing potential: Negative pregnancy test or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:\n\n  * \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago\n* Female participants of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1 until 10 months after last dose of loncastuximab tesirine and 12 months after the last dose of rituximab. Male participants with female partners of childbearing potential must agree to use a highly effective method of contraception when sexually active until 7 months after the last dose of loncastuximab tesirine.\n* Provide written informed consent and comply with the study protocol as judged by the Investigator. Of note, if the subject has an impairment that prevents him\u002Fher from providing consent, the site may follow approved institutional procedures for obtaining consent. The investigator should document when a potential or current participant lacks decision-making capacity and thus requires an LAR to provide consent.\n\nExclusion Criteria:\n\n* Concurrent use of other approved or investigational antineoplastic agents (with the exception of corticosteroids).\n* History of intracranial hemorrhage or clinically significant stroke within 6 months prior to enrollment\n* History of prior radiation to the CNS.\n* Significant medical diseases or conditions, as assessed by the investigator, that would substantially increase the risk-to-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction in the past 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, severely immunocompromised state, and congestive heart failure, New York Heart Association Class III-IV.\n* Known bleeding diathesis (e.g., von Willebrand's disease), hemophilia, or active bleeding.\n* Known Human immunodeficiency virus (HIV) infection.\n* Prior allogeneic stem cell transplant for lymphoma (autologous stem cell transplant is NOT an exclusion).\n* Prior exposure to loncastuximab tesirine\n* Chemotherapy or targeted small molecule therapy (or other therapy for CNS lymphoma) within 3 weeks prior to the first day of Lonca-R (or 5 half-lives (whichever is shorter), or 2 weeks prior to the first day of Lonca-R for monoclonal antibodies.\n* The patient must have recovered to baseline or ≤ grade 1 from prior toxicities of therapy with the exception of alopecia and myelosuppression provided lab criteria met. Recovery to ≤ grade 2 neuropathy is permitted.\n* Cellular therapy (CAR-T or Bispecific antibodies) within 8 weeks.\n* Presence of clinically significant pericardial or pleural effusions, or third space fluid accumulations (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath).\n* Congenital long QT syndrome or a corrected QT measure (QTc) interval of \\>480 ms at screening (unless secondary to pacemaker or bundle branch block).\n* Known history of hypersensitivity to CD19 antibody and\u002For, components of study medication.\n* All subjects must be screened for hepatitis B and C. Patients with evidence of active hepatitis B infection, based on positive surface antigen or Hepatitis B DNA PCR are excluded. Patients who are Hepatitis B core antibody positive must take prophylaxis with entecavir or equivalent and be willing to undergo monthly Hepatitis B DNA PCR testing. Subjects with active Hep C patients may be enrolled if other parameters precluding hepatic impairment are met and they are not undergoing active therapy for hepatitis C.\n* Active systemic bacterial, viral, fungal, or other infection requiring systemic treatment at time of screening.\n* Subjects with chronic liver disease with hepatic impairment Child-Pugh class C\n* Pregnant or lactating or intending to become pregnant during the study.\n* Patients diagnosed with another malignancy within three years or with any evidence of residual prior malignant disease (except nonmelanoma skin cancer, non-metastatic prostate cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ). Patients meeting this exclusion criteria may be enrolled after approval from study PI.\n* Unable to tolerate corticosteroids",{"count":255,"type":21},12,[24],"The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.",[259],"Central Nervous System Lymphoma",{"date":206,"type":33},{"date":262,"type":33},"2025-03-18",{"date":264,"type":21},"2030-11",{"name":39,"class":40},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":72,"sex":17,"minAge":274,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":279,"conditions":280,"keywords":283,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":245},"100549893","rural-adult-and-youth-sun-protection-study-100549893","NCT06439979","Rural Adult and Youth Sun Protection Study","Rural Adult and Youth Sun Protection Study - Rural Baseball R01","RAYS","Parent inclusion criteria:\n\ni. Adults who currently have children ages 3 and older years of age playing on participating sports teams in leagues serving rural areas in Utah or West Virginia (rural is defined as ≥4 by the RUCA or RUCC systems)\n\nii. Live and\u002For work in rural communities in Utah or West Virginia (≥4 as defined by the RUCA or RUCC systems)\n\nCoach\u002Fleader inclusion criteria:\n\ni. Adults who serve as coaches or leaders of recreational sports (i.e. baseball\u002Fsoftball, soccer, flag football, etc.) teams or developmental programs serving children ages 3 and older\n\nii. Live and\u002For work in rural areas of Utah or West Virginia (rural is defined as ≥4 by the RUCA or RUCC systems)\n\nParticipant inclusion criteria for minor participants (ages 3 and older) are as follows:\n\ni. Live in rural communities and\u002For participate in sports leagues serving rural communities in Utah or West Virginia (≥4 as defined by the RUCA or RUCC systems).\n\nParticipant inclusion criteria for key informant interviews are as follows:\n\ni. Adults who serve as leaders or who are affiliated with sports leagues or community groups serving rural youths and\u002For adults who currently have minor children 3 years of age or older playing on participating sports teams and\u002For adults who live and\u002For work in rural communities in Utah or West Virginia ((≥4 as defined by the RUCA or RUCC systems)\n\nLocal sports leagues will be eligible to participate if they convene recreational sports (i.e. baseball\u002Fsoftball) teams or developmental programs (i.e. T-ball and coach pitch) for children ages 3 and older.\n\nExclusion Criteria:\n\n* Adults and children who do not speak or read English will be excluded.\n* For individuals asked to complete surveys, individuals who have a medical or other condition (e.g., developmental delay) that would preclude their completion of these surveys will be excluded.","3 Years","7 Years",{"count":277,"type":21},843,[100],"The purpose of this study is to help prevent skin cancer by improving the use of sun protective behaviors among youths living in rural communities in Utah and West Virginia.",[281,282],"Melanoma (Skin)","Skin Cancer",[284,285,286,287,288,289],"Rural","Melanoma, Skin cancer","Prevention","Underserved communities","Youth","Sports",{"date":206,"type":33},{"date":292,"type":33},"2024-04-08",{"date":294,"type":21},"2030-04",{"name":39,"class":40},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":72,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":41},"100647696","improving-radon-education-and-awareness-in-cancer-patients-and-their-extended-community-100647696","NCT07712133","Improving Radon Education and Awareness in Cancer Patients and Their Extended Community","Inclusion Criteria:\n\n* Adult age 18 or older\n* Patient of HCI or friend\u002Ffamily or caregiver of patient of HCI (eligible if living in same home or different homes)\n* Resident of Utah, Wyoming, Idaho, Montana, or Nevada\n* Able to provide consent\n\nExclusion Criteria:\n\n* Below age 18\n* Resident of a state other than Utah, Wyoming, Idaho, Montana, or Nevada\n* Not able to provide consent",{"count":303,"type":21},200,[100],"Clinical appointments are an opportunity to provide cancer survivors (defined as patients and survivors) and people in their communities (e.g. caregivers, family members, friends) with education about radon and radon testing. This is a pilot study to develop and evaluate the impact of a clinic-based intervention that educates cancer survivors and their caregivers\u002Ffamilies about radon and radon testing. This study will enroll survivors, caregivers, and interested family members or friends in this intervention because they are important decision-makers with respect to the survivors' cancer care and well-being. This intervention would occur in clinics that treat lung cancer as well as clinics that treat cancers for which radon is being investigated as a contributor to their etiology (e.g. breast, skin melanoma, gastrointestinal).",[307],"Cancer Survivorship","2026-08-05",{"date":238,"type":33},{"date":109,"type":21},{"date":312,"type":21},"2028-06",{"name":39,"class":40},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":331,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":41},"100647407","interprofessional-simulation-program-for-clinical-resilience-and-empathy-project-inspire-100647407","NCT07707115","Interprofessional Simulation Program for Clinical Resilience and Empathy: Project INSPIRE","Interprofessional Simulation Program for Clinical Resilience and Empathy (INSPIRE) for Healthcare Teams Caring for Birthing Individuals With Substance Use Disorder in Utah","INSPIRE","Inclusion Criteria:\n\n* Employed at the University of Utah Hospital\n* Directly interfaces with birthing individuals (as clinical or non-clinical team member, e.g., physician, nurse, emergency medical technician, social worker)\n* English speaking\n\nExclusion Criteria:\n\n* Unable to provide informed consent",{"count":161,"type":21},[100],"The goal of this clinical trial is to develop and evaluate INSPIRE, an intervention for healthcare teams to improve care for individuals with substance use disorder (SUD) during their peri-delivery care. The main question it aims to answer is whether healthcare provider stigmas and behaviors change after receiving the training. The study will be implemented at the University of Utah.",[326,327,328,329,330],"Substance Use Disorders","Simulation Training","Pregnancy Related","Patient-centered Care","Bias, Implicit",[332,333],"substance use disorders","Care received in hospital during labor & delivery and post-partum",{"date":206,"type":33},{"date":336,"type":33},"2026-08-01",{"date":338,"type":21},"2027-12-31",{"name":39,"class":40},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":357,"locationsCount":41},"100642217","microvideos-for-improving-hpv-vaccination-among-childhood-cancer-survivors-100642217","NCT07648953","Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors","Inclusion Criteria:\n\n* Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.\n* Currently use Facebook or willing to create a Facebook account to use for the duration of the study.\n* At the time of enrollment, have not completed all recommended doses of the HPV vaccine.\n\nExclusion Criteria:\n\n* Unable to speak and understand English.\n* Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.\n* Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.","26 Years",{"count":348,"type":21},55,[100],"This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.\n\nUnderstanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.",[352],"HPV Vaccination",{"date":238,"type":33},{"date":109,"type":21},{"date":356,"type":21},"2027-05",{"name":39,"class":40},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":374,"locationsCount":41},"100637662","partnership-to-reduce-obesity-in-community-health-center-patients-smartlife-utah-100637662","NCT07582016","Partnership to Reduce Obesity in Community Health Center Patients (SMARTLife Utah)","Inclusion Criteria:\n\n* 18 years old or older\n* BMI ≥ 30\n* Speak either English or Spanish\n* Present at the participating clinic\n* Valid cell phone number in the electronic health record (EHR)\n* EHR indicates they have not opted out of receiving text messages from the clinic\n\nExclusion Criteria:\n\n* Currently pregnant",{"count":365,"type":21},5354,[100],"The long-term objective of SMARTLife Utah is to increase the reach of existing digital EBIs for obesity among patients of Community Health Centers (CHCs). SMARTLife Utah will be conducted in up to 11 Community Health Center (CHC) systems, consisting of 38 primary care clinics. SMARTLife Utah is a hybrid Type III effectiveness-implementation design, utilizing a pragmatic, multilevel, three-phase Sequential Multiple Assignment Randomized Trial (SMART). SMARTLife Utah leverages ubiquitous health information technology(HIT)\u002Ftelehealth for both the implementation strategies and Evidence-Based Intervention (EBI) delivery in order to address barriers for engaging in EBIs.\n\nImplementation strategies target two different levels to increase the reach of EBIs:\n\n1. a clinic-level HIT implementation strategy that includes enhanced system supports at the point of care; and\n2. patient-level implementation strategies that provide repeated opportunities to enroll in EBIs, as well as motivation\u002Fpractical problem-solving to facilitate enrollment.",[369],"Obesity",{"date":238,"type":33},{"date":109,"type":21},{"date":373,"type":21},"2029-04",{"name":39,"class":40},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":390,"leadSponsor":392,"locationsCount":41},"100637102","llm-intervention-for-tobacco-in-underserved-populations-lift-up-100637102","NCT07620301","LLM Intervention for Tobacco in Underserved Populations (LIFT-UP)","LIFT-UP","Inclusion Criteria:\n\n* 18+ years old\n* Use ≥3 cigarettes\u002Fday on average\n* Motivated to quit in the next 30 days\n* Have a computer or tablet with internet access for 1:1 interviews\n* Speak English or Spanish\n* Home address is in an area characterized by persistent poverty\n\nExclusion Criteria:\n\n* None",{"count":383,"type":21},22,[100],"This study will test a tailored, multilingual tobacco cessation chatbot called LIFT-UP (LLM Intervention for Tobacco in Underserved Populations), designed to better meet the needs of people living in persistent poverty census tracts.\n\nThis study will use 1:1 semi-structured interviews to explore social drivers of health impacting TC, as well as digital access and preferences among those living in PPCTs. This qualitative approach enables guided yet flexible exploration of key domains while capturing unanticipated insights relevant to refining the chatbot.",[387],"Smoking Cessation",{"date":238,"type":33},{"date":336,"type":21},{"date":391,"type":21},"2027-05-31",{"name":39,"class":40},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":411,"locationsCount":41},"100637034","phase-1-loncastuximab-tesirine-and-rituximab-as-first-line-therapy-in-patients-with-post-transplant-lymphoproliferative-disorder-pluto-100637034","NCT07573436","Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)","A Phase 1\u002F2 Study of Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)","PLUTO","Inclusion Criteria:\n\n* Subject aged ≥ 18 years.\n* Histologically confirmed B-cell PTLD (monomorphic and polymorphic) following solid organ transplantation; with or without EBV association.\n\n  --Note: Subjects with classic Hodgkin-like PTLD are excluded.\n* Measurable disease as defined by the 2014 Lugano Classification as assessed by positron-emission tomography (PET)- computed tomography (CT) or by CT or magnetic resonance imaging (MRI) if the tumor is not fluorodeoxyglucose (FDG)-avid on screening\n* ECOG Performance Status ≤ 2.\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Absolute neutrophil count (ANC) ≥ 1000\u002Fmm3\n    * Platelet count ≥ 75,000\u002Fmm3\n    * Hemoglobin ≥ 8 g\u002FdL\n  * Hepatic:\n\n    * Bilirubin ≤1.5 x upper limit of normal (ULN) or ≤3 x ULN with document liver involvement and\u002F or Gilbert's disease\n    * Transaminases (AST or ALT) ≤ 3 x ULN or ≤ 5 x ULN with documented liver involvement\n  * Renal:\n\n    * Estimated creatinine clearance ≥ 60 mL\u002Fmin by Cockcroft-Gault formula.\n* For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n    * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n    * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and the lactation requirements as described in Sections 5.4.1 and 5.4.2.\n* Subjects or their legal representatives must be able to read, understand, and provide informed consent to participate in the trial.\n* Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol\n\nExclusion Criteria:\n\n* PTLD following liquid transplantation\n* CNS involvement\n* Prior treatment for PTLD with the exception of radiation, antivirals, steroids and reduced immunosuppression\n* Human immunodeficiency virus (HIV) infection\n* Major surgery within 4 weeks prior to enrolment\n* History of bleeding diathesis (e.g., von Willebrand's disease), hemophilia, or active bleeding.\n* Subjects with chronic liver disease with hepatic impairment Child-Pugh class C\n* Pregnant or lactating or intending to become pregnant during the study\n* Active autoimmune disease which, in the opinion of the investigator, may negatively impact subject safety or interfere with study participation.\n* The diagnosis of another malignancy which, in the opinion of the investigator, is likely to negatively impact subject safety or interfere with study participation.\n* Significant medical diseases or conditions including those requiring substantial changes in concomitant medications, as assessed by the investigator, that would substantially increase the risk-to-benefit ratio of participating in the study. This includes, but is not limited to the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n    * Myocardial infarction (MI) within 6 months before the first dose.\n    * QTc prolongation defined as a QTcF \\> 480 ms.\n    * Congenital long QT syndrome or a corrected QT measure (QTc) interval of \\>480 ms at screening (unless secondary to pacemaker or bundle branch block).\n    * Grade 2 or higher edema (peripheral, pleural or ascites)\n    * Grade 1 or higher pericardial effusion\n  * Severe pulmonary disease\n  * Uncontrolled diabetes mellitus\n  * Severely immunocompromised state\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.\n* Active systemic bacterial, viral, fungal, or other infection requiring systemic treatment at time of screening\n* Subjects with evidence of active hepatitis B infection, based on positive surface antigen or Hepatitis B DNA PCR are excluded. Subjects who are Hepatitis B core antibody positive must take prophylaxis with entecavir or equivalent and be willing to undergo monthly Hepatitis B DNA PCR testing\n* Active hepatitis C infection\n* Grade 2 or higher rash\n* Clinically significant fluid accumulation in the third space\n* Subjects taking prohibited medications as described in Section 6.8.1. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.",{"count":402,"type":21},23,[24,53],"The purpose of phase I of this clinical trial is to learn the recommended dose of the drugs loncastuximab tesirine and rituximab in participants with post-transplant lymphoproliferative disorders (PTLD).\n\nThe purpose of phase II of this clinical trial is to learn if the drugs loncastuximab tesirine and rituximab are effective in participants with post-transplant lymphoproliferative disorders (PTLD).",[406],"Post-transplant Lymphoproliferative Disorder",{"date":238,"type":33},{"date":109,"type":21},{"date":410,"type":21},"2031-06",{"name":39,"class":40},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":162,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":426,"leadSponsor":428,"locationsCount":4},"100636774","use-of-electrical-bioimpedance-in-acute-myeloid-leukemia-aml-and-myelodysplastic-syndrome-mds-patients-bioimpedance-100636774","NCT07570056","Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)","A Pilot Study for the Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)","Inclusion Criteria:\n\n* Suspected or confirmed diagnosis of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and undergoing a bone marrow biopsy.\n* Age 18 or older.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Study prospect that has an electronic implant (cardiac, neurological, sensory, prosthetic implants with an electronic component. Also monitoring and drug delivery systems.)\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n* Pregnant women\n* Inability to understand and\u002For speak the English or Spanish language.",{"count":7,"type":21},"The goal of this project is to test non-invasive, painless skin electrical bioimpedance (BioZ) measurements as an adjunctive biomarker to standard bone marrow biopsies.",[422,423],"Myelodysplastic Syndromes","Acute Myeloid Leukemia",{"date":238,"type":33},{"date":109,"type":21},{"date":427,"type":21},"2027-07",{"name":39,"class":40},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":22,"phases":438,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":41},"100604582","phase-2-the-use-of-guarana-to-treat-fatigue-in-patients-with-neuroendocrine-tumors-and-gynecologic-cancers-guarana-fatigue-100604582","NCT07151391","The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)","The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers","Inclusion Criteria:\n\n* Subjects aged ≥ 18 years.\n* Cohort A (Neuroendocrine Tumor) Only:\n\n  ---Subjects with unresected locally advanced or metastatic well differentiated neuroendocrine tumors who are either on a watch- and-wait approach or receiving treatment with somatostatin analog(s). Patient who received and completed another active treatment but are on a \"break\" from treatment will be allowed to enroll (e.g., patients that had completed PRRT).\n* Cohort B (Gynecological Cancer) Only:\n\n  ---Subjects with early-stage (I or II) ovarian\u002Ffallopian-tube cancer in surveillance who have completed all treatment or are receiving adjuvant treatment.\n* Or\n\n  ---Subjects with endometrial cancer which is low risk, low-intermediate risk in surveillance, or high-intermediate risk receiving brachytherapy. Risk category is based on GOG criteria.\n* ECOG Performance Status ≤ 2.\n* Documentation of a score of 4 or higher when answering either of the NCCN-recommended screening questions (\"How exhausted do you feel on a scale of 0 to 10?\" or \"How impaired do you feel by this fatigue on a scale of 0 to 10?\") within 4 weeks prior to randomization\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Hemoglobin ≥ 9 g\u002FdL\n  * Hepatic:\n\n    * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN) or ≤3 x ULN with documented liver involvement and\u002For Gilbert's disease\n    * AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN ----Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.\n  * Renal:\n\n    ---Estimated creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft-Gault formula\n  * For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:\n\n    * Women \\\u003C 50 years of age:\n\n      ----Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n\n      ----Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n    * Women ≥ 50 years of age:\n\n      * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or Amenorrhea for 24 months following cessation of all exogenous hormonal treatments, if applicable; or\n      * Had radiation-induced menopause with last menses \\>1 year ago; or\n      * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n      * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n  * Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception.\n  * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* For the Neuroendocrine Tumor cohort: Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment.\n* For the Gynecological Cancer cohort: Receiving any systemic treatment besides those listed in Inclusion 3-Cohort B (Gyn only) within 6 weeks prior to the first dose of study treatment.\n* Untreated or uncontrolled endocrinopathy which is likely to significantly impact study participation.\n* History of significant autoimmune disease in the opinion of the investigator that is likely to significantly impact study participation.\n* Prior use of guarana supplements within two months of consent.\n* Self-reported \"caffeine sensitivity\" defined as excessive unwanted feelings of anxiousness, jitteriness, difficulty sleeping, or anxiety after caffeine exposure, which in the opinion of the Investigator is likely to negatively impact study participation.\n* Concurrent use of psychostimulants (e.g., lisdexamfetamine, methylphenidate).\n* Major surgery within 4 weeks prior to starting study therapy or subjects who have not fully recovered from major surgery.\n* The diagnosis of another malignancy which, in the opinion of the investigator, is likely to negatively impact subject safety or study aims.\n* Known brain metastases or cranial epidural disease.\n\n  --Note: Subjects with brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the first dose of study treatment.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  --Cardiovascular disorders:\n  * Significant symptomatic carcinoid heart disease in the opinion of the investigator\n  * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n  * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events) within 3 months before the first dose.\n  * Thromboembolic events (eg, deep venous thrombosis, pulmonary embolism) within 1 month before the first dose.\n  * QTc prolongation defined as a QTcF \\> 500 ms.\n  * Known congenital long QT.\n  * Uncontrolled hypertension per investigator assessment or grade 3 hypertension per CTCAE v.5.0\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the therapy through a feeding tube\\], social\u002F psychological issues, etc.)\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.\n\n  --Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n* Known active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.\n\n  --Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known hypersensitivity or allergy to investigational product (IP).\n* Subjects taking prohibited medications as described in Section 6.6.2 or medications for which caffeine intake is contraindicated including: β-adrenergic agonists, and\u002For medications that contain pseudoephedrine. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.",{"count":437,"type":21},86,[53],"The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers",[441,442],"Neuroendocrine Tumors","Gynecologic Cancer",{"date":444,"type":33},"2026-08-07",{"date":446,"type":33},"2025-09-03",{"date":448,"type":21},"2028-09",{"name":39,"class":40},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":72,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":471,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":41},"100529981","effect-of-sleep-extension-on-ceramides-in-people-with-overweight-and-obesity-100529981","NCT06180837","Effect of Sleep Extension on Ceramides in People With Overweight and Obesity","Biomarkers of Habitual Short Sleep and Related Cardiometabolic Risk","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 27.5-34.9 kg\u002Fm2\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease)\n3. Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg\u002FdL or HbA1c ≥6.5%\n4. Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications.\n5. Cancer that has been in remission less than 5 years\n6. Pregnant\u002Fnursing, experiencing menopause or post-menopausal\n7. Shift-work: current or history of within last year\n8. Weight change: \\>10% of body weight over prior six months\n9. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n10. Currently smoking\n11. Alcohol intake\\>14 drinks per week or \\>3 drinks per day",{"count":458,"type":21},70,[100],"The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[462,463,464,465,466,467,468,469,470],"Lifestyle Factors","Overweight and Obesity","Insulin Sensitivity","Eating Habit","Sleep Hygiene","Type 2 Diabetes","Sleep","Sleep Deprivation","Insufficient Sleep Syndrome",[472,473],"sleep","insulin sensitivity","2026-08-03",{"date":308,"type":33},{"date":477,"type":33},"2024-02-12",{"date":37,"type":21},{"name":39,"class":40},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":162,"phases":4,"briefSummary":487,"conditions":488,"keywords":493,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":41},"100524389","novel-hypoxia-imaging-for-head-and-neck-cancer-imaging-phenotype-for-personalized-treatment-100524389","NCT06108089","Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment","Inclusion Criteria:\n\n* Newly diagnosed HNSCC (head and neck squamous cell carcinoma) by biopsy or fine needle aspiration originating from the oral cavity, larynx, hypopharynx, nasopharynx, and oropharynx\n* Patients are scheduled to undergo chemoradiotherapy or surgery\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Pregnant patients\n* Patients with claustrophobia\n* Patients with pacemaker, spinal stimulator, or cochlear implant that are not MR compatible or any other metallic objects in the body\n* Patients who had been treated for HNC, either surgery, radiation therapy, or chemotherapy\n* Patients with thyroid, skin, sinonasal, and salivary gland cancer.\n* Abnormal kidney function defined as estimated glomerular filtration rate (eGRF) \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Patients with uncontrolled diabetes\n* Patients who obtained outside FDG-PET\u002FCT prior to initial treatment",{"count":98,"type":21},"Tumor hypoxia is one of the physiological factors for treatment resistance and likely contributes to poor overall survival among patients with head and neck cancer (HNC). Identifying hypoxic features of HNC may allow the personalizing treatment plan. The investigators propose multiparametric Hypoxia MR (HMR) imaging using diffusion, perfusion, and oxygenation as non-invasive, in-vivo imaging components of a hypoxia phenotype. Assessing the hypoxia phenotypes' expression will be critically important for characterizing and predicting CRT response among patients with advanced HNC.\n\nA prospective cohort study will be conducted used multiparametric MR (MPMR) imaging correlated with treatment response assessed by 3 months fluorodeoxyglucose-positron emission tomography (FDG-PET). The image analysis approach will be developed to incorporate FDG-PET and quantitative MRI characteristics of tumor (ADC, oxygen-enhanced T1 and T2\\* maps, and volume transfer constant (Ktrans) to facilitate 3D visualization of multiparametric information. This proposed study's overarching goal is to develop and validate multiparametric HMR imaging using 18F - (fluoromisonidazole) FMISO-PET and immunohistochemistry (IHC) as the standard of references.",[489,490,491,492],"Head and Neck Cancer","Hypoxia","Magnetic Resonance Imaging","Cancer Neck",[494,495,496,497],"hypoxia","precision medicine","imaging biomarker","prognosis",{"date":308,"type":33},{"date":500,"type":33},"2024-06-28",{"date":502,"type":21},"2027-12-01",{"name":39,"class":40},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":72,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":513,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":41},"100511760","circadian-intervention-to-improve-cardiometabolic-health-100511760","NCT05943626","Circadian Intervention to Improve Cardiometabolic Health","Timing of Circadian Synchronizers: The TOCS Study","TOCS","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 25.0-34.9 kg\u002Fm2,\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., diagnosed diabetes, cardiovascular disease, or kidney disease)\n3. Use of prescription drugs or substances known to influence sleep or glucose metabolism\n4. Shift-work: current or history of within last year\n5. Weight change: \\>10% of body weight over prior six months\n6. Experiencing menopause or post-menopausal\n7. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n8. Currently pregnant or planning to become pregnant, or currently lactating.\n9. Currently smoking\n10. Alcohol intake \\>3 drinks per day or \\>14 drinks per week",{"count":98,"type":21},[100],"The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[516,467,468,517,462,463,464,465,466],"Cardiometabolic Syndrome","Time Restricted Feeding",{"date":308,"type":33},{"date":520,"type":33},"2023-06-13",{"date":522,"type":21},"2027-06",{"name":39,"class":40},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":531,"enrollmentInfo":532,"targetDuration":4,"studyType":22,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":245},"100485923","neural-mechanisms-of-meditation-for-opioid-treated-chronic-low-back-pain-100485923","NCT05607381","Neural Mechanisms of Meditation for Opioid-Treated Chronic Low Back Pain","Neural Mechanisms of Meditation-Based Interventions for Chronic Low Back Pain","Inclusion Criteria:\n\n1\\) men\u002Fwomen 18-65 years of age; 2) current chronic low back pain classified according to the NIH Pain Consortium task force research standards for chronic low back pain (pain on at least half the days in the past 6 months); usual back pain ≥3 on 0-10 scale with opioid medication; and 4) current use of prescription opioids for ≥3 months.\n\nExclusion Criteria:\n\n1\\) Prior experience with MBSR, MBCT, MORE, or extensive involvement in any standardized meditation training, 2) current cancer diagnosis, 3) suicide intent or attempt in the past 30 days, 4) psychosis or moderate\u002Fsevere non-opioid substance use disorder in past 6 months; 5) persons with any electronic objects or certain metal objects in their head or body that are incompatible with MRI; 6) those who have had an abnormal brain MRI in the past; 7) those unable to lie still on their back for 1 to 1.5 hours; and 8) pregnancy.","65 Years",{"count":533,"type":21},188,[100],"The purpose of this research study is to see how a mindfulness meditation-based intervention affects pain. Specifically, we are interested in understanding the pain-relieving brain mechanisms of mindfulness meditation-based therapy for patients with opioid-treated chronic low back pain.",[537,538],"Low Back Pain","Opioid Use","2026-07-23",{"date":541,"type":33},"2026-07-27",{"date":543,"type":33},"2022-11-30",{"date":545,"type":21},"2027-06-30",{"name":39,"class":40},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":553,"maxAge":554,"enrollmentInfo":555,"targetDuration":4,"studyType":22,"phases":557,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":41},"100645888","digital-technology-informed-stroke-rehabilitation-100645888","NCT07698522","Digital Technology-Informed Stroke Rehabilitation","Inclusion Criteria:\n\n* Age between 30-85 years.\n* Diagnosis of stroke.\n* Stroke onset of at least six months prior to the time of participation.\n* Fugl Meyer Upper Extremity between 30-50 (mild-moderate)\n* Cognitive skills to consent and actively participate, as indicated by scores of ≥ 24 on the Mini- Mental Status Examination\n* Able to visit lab up to 5x per week for 3 weeks\n\nExclusion Criteria:\n\n* Presence of severe aphasia preventing the ability to follow 1-step directions at least 80% of the time.\n* Excessive spasticity of the wrist, elbow, and shoulder, defined as a Modified Ashworth Score \\>2.\n* Diagnosis of neurological disorders other than stroke.\n* Orthopedic\u002Fmusculoskeletal conditions (e.g., severe arthritis) affecting the upper extremity.\n* Currently or planning to become pregnant.\n* Participation in concurrent occupational therapy.\n* Unilateral neglect, defined as failure of the Line Bisection Task\n* Upper extremity pain \\>= 7\u002F10 on Numeric Rating Scale","30 Years","85 Years",{"count":556,"type":21},60,[100],"The goal of this study is to determine the effects of lab and home-based technology guidance during movement training post-stroke. The study will compare movement training informed by lab-based technology to training delivered with technology at home. The main questions it aims to answer are:\n\n* How well do lab and home-based technologies help individuals post-stroke improve their movement patterns?\n* Is there a difference in improvement between the in-lab and at-home training groups?\n* Which technologies lead to the most improvement?",[560],"Stroke",[562,563,564],"movement training","rehabilitation","occupational therapy","2026-07-17",{"date":567,"type":33},"2026-07-20",{"date":569,"type":21},"2026-07",{"date":571,"type":21},"2033-12",{"name":39,"class":40},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":72,"sex":17,"minAge":581,"maxAge":73,"enrollmentInfo":582,"targetDuration":4,"studyType":22,"phases":584,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":41},"100648138","digital-health-implementation-strategies-to-improve-lung-cancer-screening-among-safety-net-clinics-100648138","NCT07716280","Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics","Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics (LUNG-IS) - PATIENT","LUNG-IS","Inclusion Criteria:\n\n* Current or former, male and female, smokers.\n* Age 50-80.\n* Primary language English or Spanish.\n* Have a phone that can send\u002Freceive text messages.\n\nExclusion Criteria:\n\n* Patients who have never smoked.\n* Patients who are under the age of 50 or above the age of 80.\n* Primary language other than English or Spanish.\n* Do not have access to a phone that can send\u002Freceive text messages.","50 Years",{"count":583,"type":21},800,[100],"The long-term goal of this program of research is to increase the reach of Lung Cancer Screening (LCS) among low-resource healthcare settings and populations. The proposed project, LUNG-IS, is a mixed-methods, pre-post quasi-experimental design conducted in three Utah safety-net healthcare system clinics.\n\nLUNG-IS employs a comprehensive conceptual model with theories, models, and frameworks of implementation and behavioral science, uses rigorous mixed-methods to evaluate factors that influence implementation of LCS, and uses patient navigation to facilitate clinic-community linkages.\n\nLUNG-IS leverages existing pathways to care and Centralized Hub infrastructure that enables eligibility assessment, LCS Shared Decision Making (SDM) with clinical decision support, screening referral, and screening logistics assistance to help overcome barriers to LCS completion. The Centralized Hub model uses ubiquitous technologies (i.e., text messaging\u002Ftelehealth) to enable patients to be assessed for LCS eligibility, engage in SDM if eligible, and be referred for LCS. For patients who decide to complete LCS, they will be provided patient navigation via Community Health Workers designed to address logistical barriers, hesitancy, and financial constraints around completing LCS.",[587],"Lung Cancer","2026-07-15",{"date":590,"type":33},"2026-07-21",{"date":592,"type":33},"2026-01-01",{"date":594,"type":21},"2027-01",{"name":39,"class":40},""]